HPN217 for Multiple Myeloma

Recruiting in Palo Alto (17 mi)

+18 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

No Placebo Group

Trial Summary

What is the purpose of this trial?Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.

Eligibility Criteria

Adults over 18 with relapsed/refractory multiple myeloma who've had at least three prior treatments, including specific inhibitors and antibodies, and have measurable disease. Not for those with plasma cell leukemia, non-secretory myeloma without measurable disease, recent transplants or autoimmune diseases (with some exceptions), or a second primary malignancy not in remission for over 3 years.

Inclusion Criteria

I have recovered from the side effects of my previous treatments.

I've had 3 treatments for myeloma, including specific drugs, and can't tolerate or am not eligible for other beneficial treatments.

I am 18 years old or older.

+2 more

Exclusion Criteria

I have another cancer besides the one being treated, but it's either in remission for less than 3 years or is a low-risk type.

I had a stem cell or bone marrow transplant less than 3 months ago.

You have an autoimmune disease, except for certain conditions like vitiligo, resolved childhood eczema, or thyroid problems that are under control. If you haven't had treatment for your autoimmune disorder in the past 3 years, you may be able to participate after talking with the study doctor.

+3 more

Participant Groups

The trial is testing HPN217's safety, tolerability, and pharmacokinetics (how the drug moves through the body) in patients whose multiple myeloma has returned after treatment or hasn't responded to previous therapies.

2Treatment groups

Experimental Treatment

Group I: MK-4002 monotherapy dose escalationExperimental Treatment1 Intervention

MK-4002 is intravenously (IV) administered once weekly in escalating doses.

Group II: MK-4002 dose escalation with extended dosing intervalsExperimental Treatment1 Intervention

MK-4002 is IV administered once every 2 weeks.